1. 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial. (April 2021) Authors: Gligorov, J.; Pivot, X.; Ataseven, B.; De Laurentiis, M.; Llombart, A.; Jung, K.H.; Manikhas, A.; Azim, H.A.; Alexandrou, A.; Gupta, K.; Herraez-Baranda, L.; Tosti, N.; Restuccia, E. Journal: Breast Issue: Volume 56(2021)Supplement 1 Page Start: S21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cyclin D1 and its prognostic value in planning of endocrine therapy for women of postmenopausal age with breast cancer (5 years follow-up). (April 2018) Authors: Manikhas, A.; Skvortsov, V.; Manikhas, G.; Grinev, I.; Babeshkin, R. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of eribulin in combination with trastuzumab in HER2-positive metastatic breast cancer patients: Real life experience. (October 2020) Authors: Kovalenko, E.; Manzyuk, L.; Gorbunova, V.; Kolyadina, I.; Bolotina, L.; Zhilyaeva, L.; Ponomarenko, D.; Karabina, E.; Mukhametshina, G.; Khasanova, A.; Ekaterina, R.; Safarova, A.; Manikhas, A.; Volkonsky, M.; Kramskaya, L.; Karandeeva, T.; Suslova, I.; Popova, N.; Evstigneeva, I.; Shumskaya, I. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of eribulin in patients with metastatic breast cancer in early and late application: real life experience. (March 2019) Authors: Filonenko, D.; Gorbunova, V.; Manzyuk, L.; Kovalenko, E.; Zhukova, L.; Bolotina, L.; Kolyadina, I.; Manikhas, A.; Zhilyaeva, L.; Karabina, E. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S63 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of eribulin in patients with triple negative metastatic breast cancer: real life experience. (March 2019) Authors: Manikhas, A.; Gorbunova, V.; Manzyuk, L.; Kovalenko, E.; Bolotina, L.; Zhukova, L.; Vladimirova, L.; Kolyadina, I.; Ponomarenko, D.; Mukhametshina, G. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin. (February 2017) Authors: Rugo, H.; Barve, A.; Waller, C.; Bronchud, M.H.; Herson, J.; Yuan, J.; Manikhas, A.; Bondarenko, I.; Mukhametshina, G.; Nemsadze, G.; Parra, J.; Abesamis Tiambeng, M.L.; Baramidze, K.; Akewanlop, C.; Vynnychenko, I.; Sriuranpong, V.; Mamillapalli, G.; Ray, S.; Yanez Ruiz, E.P.; Pennella, E. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. The approach of combination of breast cancer therapy using the intraoperative radiation therapy after neoadjuvant systemic therapy. (March 2017) Authors: Manikhas, A.; Grinev, I.; Oganesyan, A.; Lee, L.; Chikrizov, S.; Manikhas, G. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. The experience in the treatment of triple negative breast cancer in St. Petersburg city clinical oncology dispensary. (April 2018) Authors: Manikhas, A.; Babeshkin, R.; Grinev, I.; Manikhas, G. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗